Comparative Pharmacology
Head-to-head clinical analysis: IBU versus RELAFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBU versus RELAFEN.
IBU vs RELAFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.
Nabumetone is a nonacidic nonsteroidal anti-inflammatory drug (NSAID) that is a prodrug, rapidly metabolized to the active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA), which inhibits cyclooxygenase (COX) and thereby prostaglandin synthesis.
200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day. For OTC use: 200-400 mg every 4-6 hours; max 1200 mg/day.
1000 mg orally once daily, or 500 mg twice daily. Maximum dose 2000 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (30 hours) and elderly (up to 6 hours). No accumulation with recommended dosing due to short t½.
Clinical Note
moderateEribulin + Digoxin
"Eribulin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateEribulin + Digitoxin
"Eribulin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateEribulin + Deslanoside
"Eribulin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateEribulin + Acetyldigitoxin
"Eribulin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 24 hours (range 20-30 hours), allowing once-daily dosing.
Renal (90% as conjugated metabolites, 10% unchanged), biliary/fecal (minor, <5%)
Primarily renal (90% as metabolites, ~5% unchanged); biliary/fecal minor (<5%).
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)